10X Genomics Inc Net Assets
10X Genomics Inc net assets. Based on the latest financial reports, 10X Genomics Inc (TXG) has net assets worth $825.55 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.03 Billion) and total liabilities ($204.52 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 10X Genomics Inc equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $825.55 Million |
| % of Total Assets | 80.14% |
| Annual Growth Rate | N/A |
| 5-Year Change | -2.6% |
| 10-Year Change | N/A |
| Growth Volatility | 28.59 |
Net Assets of 10X Genomics Inc (2017–2025)
Net assets of 10X Genomics Inc from 2017 to 2025. This chart illustrates how 10X Genomics Inc's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of 10X Genomics Inc to measure how much of total assets are equity-financed.
Annual Net Assets for 10X Genomics Inc (2017–2025)
The table below shows the annual net assets of 10X Genomics Inc from 2017 to 2025. For live market cap and overall valuation, see 10X Genomics Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $796.33 Million | +12.14% |
| 2024-12-31 | $710.13 Million | -4.17% |
| 2023-12-31 | $741.04 Million | -8.03% |
| 2022-12-31 | $805.74 Million | -1.45% |
| 2021-12-31 | $817.57 Million | +10.62% |
| 2020-12-31 | $739.07 Million | +75.93% |
| 2019-12-31 | $420.08 Million | +290.96% |
| 2018-12-31 | $-219.99 Million | -95.53% |
| 2017-12-31 | $-112.51 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to 10X Genomics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 139196000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
10X Genomics Inc Net Assets Breakdown (December 2025)
10X Genomics Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.00% |
| Other Comprehensive Income | $225.00K | 0.03% |
| Other Components | $2.31 Billion | 289.67% |
| Total Equity | $796.33 Million | 100.00% |
10X Genomics Inc Competitors by Market Cap
The table below lists competitors of 10X Genomics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Columbia Banking System Inc
NASDAQ:COLB
|
$8.44 Billion |
|
NHPC Limited
NSE:NHPC
|
$8.45 Billion |
|
Menora Miv Hld
TA:MMHD
|
$8.47 Billion |
|
Alpha Services and Holdings S.A.
AT:ALPHA
|
$8.47 Billion |
|
ALIB.HL.INF.TEC.UNSP.ADR
F:TWYA
|
$8.42 Billion |
|
Match Group Inc
NASDAQ:MTCH
|
$8.41 Billion |
|
Shanghai Commercial & Savings Bank Ltd
TW:5876
|
$8.41 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
$8.40 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 10X Genomics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 710,134,000 to 796,326,000, a change of 86,192,000 (12.1%).
- Net loss of 43,544,000 reduced equity.
- Other comprehensive income increased equity by 718,000.
- Other factors increased equity by 129,018,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-43.54 Million | -5.47% |
| Other Comprehensive Income | $718.00K | +0.09% |
| Other Changes | $129.02 Million | +16.2% |
| Total Change | $- | 12.14% |
Book Value vs Market Value Analysis
This analysis compares 10X Genomics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.98x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-9.71 | $70.11 | x |
| 2018-12-31 | $-16.43 | $70.11 | x |
| 2019-12-31 | $5.37 | $70.11 | x |
| 2020-12-31 | $7.31 | $70.11 | x |
| 2021-12-31 | $7.41 | $70.11 | x |
| 2022-12-31 | $7.08 | $70.11 | x |
| 2023-12-31 | $6.32 | $70.11 | x |
| 2024-12-31 | $5.90 | $70.11 | x |
| 2025-12-31 | $6.38 | $70.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 10X Genomics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.77%
- • Asset Turnover: 0.62x
- • Equity Multiplier: 1.31x
- Recent ROE (-5.47%) is above the historical average (-19.36%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -26.39% | 0.94x | 0.00x | $-7.51 Million |
| 2018 | 0.00% | -76.88% | 1.18x | 0.00x | $-90.49 Million |
| 2019 | -7.44% | -12.71% | 0.41x | 1.44x | $-73.26 Million |
| 2020 | -73.43% | -181.61% | 0.32x | 1.26x | $-616.64 Million |
| 2021 | -7.12% | -11.87% | 0.48x | 1.25x | $-139.98 Million |
| 2022 | -20.60% | -32.15% | 0.50x | 1.28x | $-246.57 Million |
| 2023 | -34.42% | -41.23% | 0.64x | 1.30x | $-329.20 Million |
| 2024 | -25.72% | -29.90% | 0.66x | 1.29x | $-253.64 Million |
| 2025 | -5.47% | -6.77% | 0.62x | 1.31x | $-123.18 Million |
Industry Comparison
This section compares 10X Genomics Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $3,883,148,510
- Average return on equity (ROE) among peers: -152.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 10X Genomics Inc (TXG) | $825.55 Million | 0.00% | 0.25x | $8.43 Billion |
| Abbott Laboratories (ABT) | $38.83 Billion | 14.74% | 0.89x | $184.67 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $2.26 Million |
| Aethlon Medical Inc (AEMD) | $5.12 Million | -261.31% | 0.44x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $75.02 Million | -52.81% | 0.78x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $786.82 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $1.53 Million | -361.86% | 1.36x | $2.20 Million |
| Allurion Technologies, Inc. (ALUR) | $-34.28 Million | 0.00% | 0.00x | $21.01K |
| Autonomix Medical, Inc. Common Stock (AMIX) | $1.96 Million | -680.21% | 0.05x | $1.76 Million |
| Artivion Inc (AORT) | $6.60 Million | -10.61% | 0.65x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $6.01 Million | -36.31% | 0.22x | $109.52 Million |
About 10X Genomics Inc
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related… Read more